NONOF — NOVO NORDISK A S
—
NYSE ·
Health Care ·
Pharmaceuticals ·
CIK 353278 ·
Last close
$48.68
Market Cap
$163.07B
52W High
$50.80
52W Low
$35.21
ADV30
10,620
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 96,823,000,000 | 83,225,000,000 | 59,618,000,000 | 48,557,000,000 | 559,221,000,000 | 21,127,000,000 | 356,156,000,000 |
| Dec 2025 | 79,144,000,000 | 63,996,000,000 | 31,736,000,000 | 26,891,000,000 | 542,902,000,000 | 26,464,000,000 | 348,855,000,000 |
| Sep 2025 | 74,976,000,000 | 57,072,000,000 | 23,682,000,000 | 20,006,000,000 | 512,288,000,000 | 32,084,000,000 | 342,392,000,000 |
| Jun 2025 | 76,857,000,000 | 64,011,000,000 | 33,449,000,000 | 26,503,000,000 | 482,153,000,000 | 18,435,000,000 | 314,087,000,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$118,456,000,000
Investing CF
$-84,891,000,000
Financing CF
$-50,459,000,000
CapEx
$-87,566,000,000
Dividends Paid
$-51,801,000,000
Buybacks
$-2,400,000,000
EPS Diluted TTM
$29.44
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$206,420,000,000
Inventory
$51,352,000,000
Receivables
$100,268,000,000
ST Investments
$499,000,000
EBIT TTM
$159,852,000,000
Pretax Income TTM
$155,679,000,000
Interest Exp TTM
$9,234,000,000
Analysts
1
Yahoo Snapshot (yfinance, live)
Total Revenue
$327,799,996,416
EBITDA
$173,876,002,816
Free Cash Flow
$-12,039,249,920
Enterprise Value
$338,897,698,816
Total Cash
$21,625,999,360
Total Debt
$146,381,996,032
Shares Out
3,349,933,520
Trailing EPS
$4.17
Book Value
$6.97
ROE
71.4%
ROA
19.2%
Div Yield
3.71%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 309,064,000,000 | 127,658,000,000 | 102,434,000,000 | 542,902,000,000 | 348,855,000,000 | — | 119,102,000,000 |
| Dec 2024 | 290,403,000,000 | 128,339,000,000 | 100,988,000,000 | 465,630,000,000 | 322,144,000,000 | — | 120,968,000,000 |
| Dec 2023 | 232,261,000,000 | 102,574,000,000 | 83,683,000,000 | 314,486,000,000 | 207,925,000,000 | — | 108,908,000,000 |
| Dec 2022 | 176,954,000,000 | 74,809,000,000 | 55,525,000,000 | 241,257,000,000 | 157,771,000,000 | — | 78,887,000,000 |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | $163.61B | $93.93 | — |
| NVO | NOVO NORDISK A S | $165.75B | $49.48 | — |
| PFE | PFIZER INC | $137.76B | $24.17 | — |
| VRTX | VERTEX PHARMACEUTICALS INC / MA | $123.19B | $485.39 | — |
| BMY | BRISTOL MYERS SQUIBB CO | $117.58B | $57.58 | — |
News headlines (Yahoo Finance, 1h cache)
Is Pfizer on Track to Launch Its Next Lipitor -- This Time in the Weight-Loss Market?
2026-07-10 23:35 · Yahoo
NVO Rallies 11% in a Month: How Should Investors Play the Stock?
2026-07-10 14:11 · Yahoo
AI Revolutionizes Cardiovascular Drug Development with $1.4+ Billion in Strategic Investments
2026-07-10 14:06 · Yahoo
Novo Nordisk A/S (NVO) is Attracting Investor Attention: Here is What You Should Know
2026-07-10 13:00 · Yahoo
Here's Why Shares in Novo Nordisk Rival, Agios Pharmaceutical, Soared This Week
2026-07-10 11:55 · Yahoo
Record Numbers of Americans Are on GLP-1 Drugs. That's Great News for This Stock.
2026-07-09 19:57 · Yahoo
Novo Nordisk (NVO) In Focus After Wegovy Label Update As Undervalued Narrative Holds
2026-07-09 18:21 · Yahoo
Novo Nordisk (NYSE:NVO) Updates Wegovy Label In Singapore With STEP UP Data
2026-07-09 17:13 · Yahoo
Two Drugmakers Own 90% of the Obesity Boom. One Fund Owns Both for 0.59%
2026-07-09 16:18 · Yahoo
Novo Nordisk (CPSE:NOVO B) Could Be 13% Overvalued Following Its Vivani Deal
2026-07-09 16:12 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.